Direct Oral Anticoagulant Use: A Practical Guide to Common
ABSTRACT: Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular con - ditions.
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. 1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie,
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long‐standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions.
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions. Since the first approval in 2010, DOACs have emerged a
Management of Anticoagulation Therapy - American Society
information in this pocket guide is intended to support patients, clinicians, and other health care professionals in making evidence-based decisions about the management of commonly prescribed anticoagulant drugs for the prevention and treatment of VTE. This guide assumes the selection of the specific anticoagulant medication has already been made.
- What are direct oral anticoagulants?
- Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions. Since the first approval in 2010, DOACs have emerged a …
- What are direct oral anticoagulants (DOACs)?
- 3 Center for Preventive Cardiology Knight Cardiovascular Institute Oregon Health & Science University Portland OR. Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist.
- Are direct oral anticoagulants a good alternative to vitamin K antagonist?
- ABSTRACT: Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long- standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular con-ditions.
- What are DOACs & how do they work?
- DOACs have revolutionized anticoagulant management and are becoming the cornerstone treatment for stroke prevention in AF and VTE prophylaxis and treatment, and the list of other indications is expanding.
- How effective are DOACs for venous thromboembolism?
- DOACs have been found to be at least as safe and effective as vitamin K antagonists in randomised, controlled trials for stroke prevention in AF and the management of venous thromboembolism, with real-world data showing similar outcomes. With the availability of several agents, selecting the most appropriate DOAC can be challenging.
- Why do clinicians need a DOAC?
- With the expanding role of DOACs, clinicians are faced with increasingly complex decisions relating to appropriate agent, duration of treatment, and use in special populations. This review will provide an overview of DOACs and act as a practical reference for clinicians to optimize DOAC use among common challenging scenarios.
